Progress and challenges towards targeted delivery of cancer therapeutics

Daniel Rosenblum; Nitin Joshi; Wei Tao; Jeffrey M. Karp; Dan Peer

doi:10.1038/s41467-018-03705-y

Progress and challenges towards targeted delivery of cancer therapeutics

Daniel Rosenblum, Nitin Joshi, Wei Tao, Jeffrey M. Karp, Dan Peer

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

Original language	English
Article number	1410
Journal	Nature Communications
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41467-018-03705-y
State	Published - 1 Dec 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Chemistry
General Biochemistry,Genetics and Molecular Biology
General Physics and Astronomy

Access to Document

10.1038/s41467-018-03705-y

Cite this

@article{9e65f9cb0acb444b8c6b8e0f39525be9,

title = "Progress and challenges towards targeted delivery of cancer therapeutics",

abstract = "Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.",

author = "Daniel Rosenblum and Nitin Joshi and Wei Tao and Karp, \{Jeffrey M.\} and Dan Peer",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41467-018-03705-y",

language = "الإنجليزيّة",

volume = "9",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Progress and challenges towards targeted delivery of cancer therapeutics

AU - Rosenblum, Daniel

AU - Joshi, Nitin

AU - Tao, Wei

AU - Karp, Jeffrey M.

AU - Peer, Dan

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

AB - Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have advanced past clinical trials. Herein, we review the principles behind targeted delivery approaches to determine potential reasons for their limited clinical translation and success. We propose criteria and considerations that must be taken into account for the development of novel actively targeted NCs. We also highlight the possible directions for the development of successful tumor targeting strategies.

UR - http://www.scopus.com/inward/record.url?scp=85045523734&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-03705-y

DO - 10.1038/s41467-018-03705-y

M3 - مقالة مرجعية

C2 - 29650952

SN - 2041-1723

VL - 9

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1410

ER -

Progress and challenges towards targeted delivery of cancer therapeutics

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this